Trials / Not Yet Recruiting
Not Yet RecruitingNCT05901025
Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients
Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients: A Multi-center, Prospective, Observational Study
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,000 (estimated)
- Sponsor
- Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn about the mutation spectrum of homologous recombination repair pathway genes and its instructive significance in the treatment of Chinese breast cancer patients.
Detailed description
The main questions it aims to answer are: 1. What is the mutation spectrum of homologous recombination repair pathway genes in Chinese breast cancer patients? 2. Does homologous recombination repair pathway gene mutation have an impact on patient outcome (breast cancer recurrence, neoadjuvant chemotherapy efficacy, treatment decisions, etc.) ? There is no intervention on participants, but all participants will be given regular follow-up post surgery according to ASCO guidelines.
Conditions
Timeline
- Start date
- 2023-06-05
- Primary completion
- 2028-06-30
- Completion
- 2033-06-30
- First posted
- 2023-06-13
- Last updated
- 2023-06-13
Source: ClinicalTrials.gov record NCT05901025. Inclusion in this directory is not an endorsement.